How much weight loss was seen in the STEP 1 semaglutide trial?

What question did the researchers ask?

Adults with overweight plus a related condition, or obesity, and without diabetes were assigned to weekly semaglutide 2.4 mg or placebo for 68 weeks; both groups also received lifestyle intervention.

What did they actually find?

Average weight change was −14.9% with semaglutide and −2.4% with placebo. More participants reached 5%, 10% and 15% loss thresholds, while nausea and diarrhoea were common and gastrointestinal effects caused more discontinuations.

What should you keep in mind?

This was a specific dose, population and monitored trial funded by the manufacturer. Prescribing still requires eligibility checks, contraindication review, side-effect planning and long-term support; response and weight regain vary.

What does this mean for a Highfield consultation?

A landmark trial supports one option alongside lifestyle support; suitability, contraindications and follow-up still apply. We consider that finding alongside independent guidance, your medical history, examination and priorities. It can support a better-informed decision, but it cannot promise a personal result or decide whether treatment is suitable.